Cargando…
Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076857/ https://www.ncbi.nlm.nih.gov/pubmed/37035159 http://dx.doi.org/10.3389/fonc.2023.1144875 |
_version_ | 1785020227965157376 |
---|---|
author | Da, Liangshan Qu, Ziting Zhang, Congjun Shen, Yuanyuan Huang, Wei Zhang, Yiyin Gu, Kangsheng |
author_facet | Da, Liangshan Qu, Ziting Zhang, Congjun Shen, Yuanyuan Huang, Wei Zhang, Yiyin Gu, Kangsheng |
author_sort | Da, Liangshan |
collection | PubMed |
description | PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analysis, Youden’s indexes were applied to determine the cut-off values for inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocye ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Wilcoxon test was conducted to evaluate the changes in above inflammatory markers. Kaplan-Meier method was utilized to estimate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used to compare the different survival between groups. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of inflammatory markers and clinical features. RESULTS: 162 advanced or metastatic ESCC patients receiving anti-PD-1 treatment were enrolled in this retrospective study. The cut-off values of NLR, dNLR, MLR, PLR, and SII were 4.748, 2.214, 0.309, 250.505, and 887.895, respectively. NLR, dNLR, PLR, and SII declined significantly among the partial response (PR) (P<0.001, P<0.001, P=0.036, P<0.001), objective response rate (ORR) (P<0.001, P<0.001, P=0.036, P<0.001), and disease control rate (DCR) (P<0.001, P<0.001, P=0.038, P<0.001) groups, respectively. Significant increases were found in NLR (P<0.001), dNLR (P<0.001), MLR (P=0.001), and SII (P=0.024) when anti-PD-1 treatment failed. Multivariate Cox regression analysis indicated that NLR (P<0.001, P=0.002), lymph node metastasis (P=0.013, P=0.001), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (P=0.008, P=0.002), and treatment lines (P=0.037, P=0.048) were significant prognostic indicators of PFS and OS. Additionally, SII (P=0.016) was also significantly related to OS in ESCC patients. The risk score model showed that low risk patients prolonged PFS and OS than those with middle or high risk (P<0.001, P<0.001). CONCLUSION: Inflammatory markers can reflect short-term outcomes of anti-PD-1 treatment for ESCC patients. NLR, lymph node metastases, ECOG PS, and treatment lines are significant prognostic indicators for PFS and OS. And the risk score model constructed based on the above factors has favourable prognostic predictive value. |
format | Online Article Text |
id | pubmed-10076857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100768572023-04-07 Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment Da, Liangshan Qu, Ziting Zhang, Congjun Shen, Yuanyuan Huang, Wei Zhang, Yiyin Gu, Kangsheng Front Oncol Oncology PURPOSE: This study aims to assess the prognostic value of inflammatory markers and clinical features in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients receiving anti-programmed death 1 (PD-1) treatment. METHODS: Based on receiver operating characteristic curve (ROC) analysis, Youden’s indexes were applied to determine the cut-off values for inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocye ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Wilcoxon test was conducted to evaluate the changes in above inflammatory markers. Kaplan-Meier method was utilized to estimate progression-free survival (PFS) and overall survival (OS), and the Log-rank test was used to compare the different survival between groups. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of inflammatory markers and clinical features. RESULTS: 162 advanced or metastatic ESCC patients receiving anti-PD-1 treatment were enrolled in this retrospective study. The cut-off values of NLR, dNLR, MLR, PLR, and SII were 4.748, 2.214, 0.309, 250.505, and 887.895, respectively. NLR, dNLR, PLR, and SII declined significantly among the partial response (PR) (P<0.001, P<0.001, P=0.036, P<0.001), objective response rate (ORR) (P<0.001, P<0.001, P=0.036, P<0.001), and disease control rate (DCR) (P<0.001, P<0.001, P=0.038, P<0.001) groups, respectively. Significant increases were found in NLR (P<0.001), dNLR (P<0.001), MLR (P=0.001), and SII (P=0.024) when anti-PD-1 treatment failed. Multivariate Cox regression analysis indicated that NLR (P<0.001, P=0.002), lymph node metastasis (P=0.013, P=0.001), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (P=0.008, P=0.002), and treatment lines (P=0.037, P=0.048) were significant prognostic indicators of PFS and OS. Additionally, SII (P=0.016) was also significantly related to OS in ESCC patients. The risk score model showed that low risk patients prolonged PFS and OS than those with middle or high risk (P<0.001, P<0.001). CONCLUSION: Inflammatory markers can reflect short-term outcomes of anti-PD-1 treatment for ESCC patients. NLR, lymph node metastases, ECOG PS, and treatment lines are significant prognostic indicators for PFS and OS. And the risk score model constructed based on the above factors has favourable prognostic predictive value. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076857/ /pubmed/37035159 http://dx.doi.org/10.3389/fonc.2023.1144875 Text en Copyright © 2023 Da, Qu, Zhang, Shen, Huang, Zhang and Gu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Da, Liangshan Qu, Ziting Zhang, Congjun Shen, Yuanyuan Huang, Wei Zhang, Yiyin Gu, Kangsheng Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title | Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title_full | Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title_fullStr | Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title_full_unstemmed | Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title_short | Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
title_sort | prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076857/ https://www.ncbi.nlm.nih.gov/pubmed/37035159 http://dx.doi.org/10.3389/fonc.2023.1144875 |
work_keys_str_mv | AT daliangshan prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT quziting prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT zhangcongjun prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT shenyuanyuan prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT huangwei prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT zhangyiyin prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment AT gukangsheng prognosticvalueofinflammatorymarkersandclinicalfeaturesforsurvivalinadvancedormetastaticesophagealsquamouscellcarcinomapatientsreceivingantiprogrammeddeath1treatment |